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. RTKs are under tight control by several modes of regulation, the best-studied of which are production -both transcriptional and post-transcriptional -and ligand availability. As such, aberrant RTK activation in cancer is often caused by gene amplification, receptor overexpression, autocrine activation or gain-of-function mutations. However, mounting evidence suggests that RTKs are also subject to tight spatial control, in both individual cells and multicellular tissues. Indeed, RTKs first appeared evolutionarily during the transition to multicellularity as cells developed more complex and compartmentalized ways of interacting with their environment 2, 3 . Although it was originally assumed that the ligandinduced activation of a given RTK could occur indiscriminately throughout the plasma membrane, it is now appreciated that receptors are neither uniformly distributed nor uniformly activated across the cell cortex 4 . The past two decades of research have revealed that the plasma membrane is highly and dynamically compartmentalized and have suggested that this partitioning (lateral spatial control) has a crucial role in controlling RTK signalling. Moreover, RTK signalling is not limited to the cell surface, but can continue from within the endocytic compartment (axial spatial control). In fact, specific endocytic pathways can direct RTKs to subcellular compartments from which they can activate distinct intracellular pathways. Importantly, both at the cell surface and in intracellular compartments, active RTKs also recruit feedback and feedforward components (such as phosphatases, downstream kinases and ubiquitin ligases) to form signalling nodes that magnify the spatial aspect of their output. These multiple modes of spatial control allow the cell to autonomously finetune its response to a given environmental stimulus. In turn, the mechanisms used by individual cells to spatially control RTK activity are coordinated to control the development, homeostasis and movement of multicellular tissues. Given that spatial regulation of RTKs is essential for many aspects of normal development and tissue homeostasis, and that RTK activity drives many types of cancer, aberrant spatial regulation of RTKs is likely to have an underappreciated role in cancer development and progression. In this Review we discuss how normal cells and tissues spatially control RTK activity. We present specific examples of spatially deregulated RTKs in cancer and consider how spatial RTK deregulation might underlie other well-known hallmarks of tumorigenesis. Finally, we address the need for a greater understanding of how the spatial regulation of RTKs could affect ongoing efforts to therapeutically target RTKs -a major challenge in the treatment of human cancer. Active RTK dimer which the ligand directly or indirectly stabilizes the interaction between two receptors 5, 6 . However, increasing evidence from structural and other studies indicates that many RTKs also form dimers and higher order oligomers (clusters) in the absence of ligand; such ligandindependent receptor clusters may be either active or 'primed' for ligand-dependent activation 4, [7] [8] [9] [10] [11] [12] [13] [14] . As monomeric RTKs cannot activate downstream signalling owing to cis-autoinhibition of the tyrosine kinase domain, which is released only after receptor dimerization 6 , the control of the abundance and distribution of individual RTKs at the membrane is a key rate-limiting step in receptor activation -a step that dictates not only how likely it is that a given receptor will dimerize or cluster, but also the identity of its interacting partner or partners (FIG. 1) .
Mechanisms of RTK spatial regulation
The effective RTK surface abundance is controlled by the intracellular production of receptors, delivery to and turnover of receptors at the plasma membrane, and the compartmentalization of receptors within the plasma membrane -processes that are tightly integrated (FIG. 2a) . In the absence of ligand, the abundance of unstimulated receptors at the cell surface is controlled via production and continuous recycling. On stimulation, ligand-dependent internalization can result in either receptor recycling or degradation, depending on the identity of the receptor, on the ligand concentration, and/or on the tight spatial control of both receptors and endocytic machinery across the cell cortex.
It is now appreciated that the plasma membrane is not homogeneous; rather, it is partitioned into nanometre-scale domains that can dramatically affect receptor distribution and signalling [15] [16] [17] [18] [19] . These domains are created by the differential distribution of lipids and proteins together with the underlying cortical cytoskeleton -a meshwork of actin filaments and other cytoskeletal components that is closely apposed to the plasma membrane. The interaction of cytoskeletal proteins with membrane lipids and/or transmembrane receptors and associated protein complexes can corral, or 'fence in' , many types of receptors, including RTKs, within the membrane, increasing or decreasing their propensity to cluster and signal 20, 21 . Studies of epidermal growth factor receptor (EGFR; also known as ERBB1) (BOX 1) clustering across the plasma membrane have revealed a surprisingly heterogeneous and variable distribution of dimers and higher order clusters across the membrane of individual cells 10, [22] [23] [24] . Although little is known about the clustering of other EGFR family members (ERBB2, ERBB3 and ERBB4), the distribution of EGFR, ERBB2 and ERBB3 within the same cell can be markedly different, highlighting how little we know about the spatial control of this therapeutically crucial family of RTKs 12, 23, 25 . The effect that spatial control can have on RTK signalling is exemplified by studies of EPH RTKs and their transmembrane ligands, ephrins. For example, restricting the lateral distribution of activated EPHA2 receptors prevents the coalescence of microclusters
Box 1 | Receptor tyrosine kinases
The mammalian receptor tyrosine kinase (RTK) superfamily of transmembrane receptors includes at least 58 members that share a conserved architecture (reviewed in REFS 1, 6) . Epidermal growth factor receptor (EGFR) was the first RTK discovered and the first that was found to be directly mutated in human cancer 130 . As such it has served as the prototype for understanding RTKs. Early studies led to the canonical view that EGFR and other RTKs are activated via ligand-induced dimerization, kinase activation and transphosphorylation of the cytoplasmic domain, creating docking sites for phosphotyrosine-binding effectors that initiate intracellular signalling cascades (see the Figure) . It is generally thought that the broad array of signalling input to RTKs converges on a relatively small number of intracellular cascades. However, the signalling output can vary widely, depending on the temporal and spatial activation of RTKs.
Interest in therapeutically targeting EGFR and other members of the EGFR (also known as ERBB) family in cancer has prompted renewed investigation into how these RTKs are activated and pharmacologically inhibited. For example, structural and other studies have suggested more sophisticated mechanisms of ERBB partnering, activation and ligand-independent clustering 8, 10, 12, 13, [131] [132] [133] . Translational studies have yielded detailed and often unexpected insight into how pharmacological inhibitors affect ERBB activity (reviewed in REFS 134, 135) . Developmental studies have revealed complex patterns of EGFR activity that drive tissue morphogenesis 61, 136 , and molecular and systems-based studies have identified the importance of signal branching, feedback and phosphatase-mediated control in propagating and tuning the ligand-initiated response 137, 138 . These studies have advanced our understanding of ERBB signalling, but have also revealed gaps in our knowledge. Moreover, this 'circumstantially driven' focus on ERBB receptors might have obscured the importance of other RTKs: for example, the discoidin domain receptors, which regulate the interactions of cells with their surrounding collagen matrix 139 , and the EPHs, which are activated by membrane-bound ligands on adjacent cells and are members of the largest and evolutionarily most rapidly expanding RTK subfamily 36 . JAK, Janus kinase; PKC, protein kinase C;
PLCγ, phospholipase C-γ; STAT, signal transducer and activator of transcription. into higher order clusters and alters signalling output 26 . Indeed, the organization of the cortical cytoskeleton itself is likely to have a key role in controlling RTK clustering. For example, a recent study suggests that cortical actin can promote the asymmetric distribution of preformed EGFR dimers, possibly enabling cells to rapidly respond to stimuli in a polarized manner, such as during directed cell migration 13 . Thus, RTK distribution and signalling can be linked to the physical properties of the cell cortex via the organization of the cortical cytoskeleton. These studies provide just a glimpse into how cells might exploit this underappreciated spatial dimension of RTK control to sense and to respond to a dynamic environment.
Plasma membrane
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Compartmentalization of the cell cortex can also influence the trafficking of receptors to and from the cell surface by affecting the distribution of the endocytic machinery itself 15, 27, 28 (FIG. 2a) . For example, clathrincoated structures can assemble from pre-designated membrane domains that sequester clathrin and other endocytic proteins to facilitate rapid and repetitive endocytosis 29, 30 . Increasing evidence suggests that the distribution of such clathrin 'hot spots' is dependent on the cortical cytoskeleton 29, 30 . Alternatively, regions of the plasma membrane that are enriched in cholesterol and sphingolipids known as lipid rafts (also known as sterol-or detergent-rich membrane domains) can also profoundly affect the distribution and endocytosis of RTKs 18, 31 (FIG. 2a) . Depending on the receptor and cellular context, lipid raft localization can enhance or prevent RTK internalization and signalling by affecting receptor association with components of the endocytic machinery. Thus, some studies have concluded that lipid raft association promotes EGFR signalling but others have concluded that EGFR is activated on release from lipid rafts 32 . Internalization of RTKs from lipid rafts occurs in a clathrin-independent manner and can yield an outcome that is distinct from clathrin-dependent endocytosis. For example, in some cells, lipid raft-internalized EGFR is preferentially routed to the lysosome for degradation, and clathrin-internalized EGFR is recycled 33 . Thus, the localization of EGFR to lipid rafts versus clathrin-rich regions can greatly affect its surface abundance and, consequently, its signalling. Similarly, the RTK RET associates with different adaptor proteins whether it is localized within or outside lipid rafts, which might dictate the duration and biological outcome of downstream signalling 34 .
Lipid rafts can also function as platforms for the assembly of membranous and cytoplasmic signalling molecules, the lateral clustering of which forms a signalling compartment that is well segregated from nonraft proteins. For example, on interaction with the RTK EPHB2, the transmembrane ligand ephrin B1 clusters in lipid rafts where it recruits and activates a multiprotein signalling complex 35, 36 . Alternatively, lipid raft-association of a ligand can prevent autocrine activation of its cognate RTK. For example, autocrine activation of the
At a glance
• The deregulation of receptor tyrosine kinases (RTKs) has been implicated in nearly all forms of human cancer. As such, RTKs are the subject of major ongoing efforts to develop targeted cancer therapies. • Because of their broad roles in many crucial cellular processes, RTKs are subject to tight regulation. The regulation of RTK production has been well studied; mounting evidence indicates that spatial regulation of RTKs is also important.
• RTKs are spatially regulated in two dimensions -lateral and axial. The heterogeneous nature of the plasma membrane yields lateral compartmentalization of RTKs to both nanometre-scale and much larger macrodomains. Axial control of RTKs via endocytosis enables differential signalling from the plasma membrane and/or endosomes.
• The spatial distribution of RTKs is important for many developmental processes, including directed cell migration and branching morphogenesis. Regulated RTK distribution is also necessary for spatial patterning during cell fate specification and tissue homeostasis.
• There are many ways in which deregulated spatial control of RTKs may contribute to tumorigenesis. For example, increased RTK production can yield altered plasma membrane distribution and clustering, defective tissue architecture can promote abnormal receptor-receptor and/or receptor-ligand interactions, and defects in vesicular trafficking can increase surface RTK levels and affect the location from which signalling occurs (for example, the plasma membrane versus the endosome).
• Despite accumulating evidence, the effect of spatial RTK signalling in tumorigenesis and therapeutic response is underappreciated. A three-dimensional view of RTK activity in tumour cells and tissues could yield a more complete understanding of the mechanisms of tumour progression and therapeutic resistance, leading to altered treatment strategies. 
Tight junctions
Cell-cell adhesion complexes that form a semi-permeable barrier between the apical and basolateral surfaces of epithelial cells and that contribute to cell polarity and signalling.
Apical-basal polarity
Epithelial cells are polarized, with an apical membrane that faces the external environment or a lumen and a spatially opposed basolateral membrane that functions in cell-cell interactions and contacts the basement membrane.
non-raft-associated RTK fibroblast growth factor receptor (FGFR) in skeletal muscle can be prevented by the sequestration of its ligand, FGF2, in lipid rafts 37 .
Membrane distribution of RTKs in tissues.
Beyond the nanometre-scale domains formed in the plasma membrane of individual cells, cells within tissues work together to establish larger macrodomains of the plasma membrane that affect receptor distribution. These macrodomains are both established within individual cells and coordinated among cells in a tissue 38 . Central to this coordination are the contacts between cells that establish membrane asymmetry and that allow cells to physically sense and respond to one another. For example, epithelial cell-cell junctions (adherens junctions and tight junctions) form a boundary that segregates the membrane into apical and basolateral domains, distinct lipid-protein environments to which RTKs are differentially recruited and retained 39 (FIG. 3) . Epithelial cell-cell junctions are thought to both provide a positional cue for the maintenance of apical and basolateral membranes (and thus, apical-basal polarity) via protein trafficking and to form a molecular 'fence' that physically prevents the diffusion of receptors and other membrane proteins . ERBB2 is a unique RTK in that it does not require ligand binding for activation; thus, increased surface levels of ERBB2 lead to ligand-independent clustering and downstream signalling 135 . ERBB2 amplification or overexpression also allows for increased heterodimerization with, and therefore activation of, other ERBB family members. Finally, mutations in RTKs themselves can affect their lateral or axial distribution and signalling. Nature Reviews | Cancer 
PDZ domain
A structural, protein-protein interaction domain of ~80-90 amino acids in length that often serves as a scaffold for signalling complexes and/or as a cytoskeletal anchor for transmembrane proteins.
from one domain to the other. Regulated vesicular transport between these two domains, known as transcytosis, or the breakdown of the tight junction is required for proteins on one side to interact with those on the other. Therefore, this boundary can have a dramatic effect on the clustering of RTKs and/or on their interaction with cell-autonomously provided (autocrine) ligands. Moreover, given that growth factors can be specifically presented to the apical or basolateral surfaces via other cell types, extracellular matrix or body fluids, this boundary can also dictate whether a given receptor can respond to non-cell-autonomous (paracrine) sources of ligand (FIG. 3) .
The biological importance of spatially controlling the polarized distribution of RTKs in vivo was first recognized in Caenorhabditis elegans. The worm has a single EGFR family member, LET-23, the function of which is crucial for the development of the vulva -the egg-laying organ 40, 41 . During vulval development, the anchor cell secretes the EGF-like ligand LIN-3 to activate LET-23 on the basolateral surface of adjacent vulval precursor cells and to specify primary vulval cell fate. In 1996, Hoskins et al. and Simske et al. reported that loss-of-function mutations in genes encoding the PDZ domain-containing proteins LIN-2 or LIN-7 cause apical mislocalization of LET-23 and abrogate its function in vulval cell fate determination 42, 43 . Thus, LET-23 must be localized to the basolateral surface of the vulval precursor cells facing the anchor cell in order to receive the paracrine anchor cell-derived signal.
An example of the cell-autonomous segregation of receptor and ligand is provided by studies of the human airway epithelium, which constitutively secretes the growth factor neuregulin (NRG) and expresses its receptors, ERBB3 and ERBB4. Despite the ability of NRG-activated ERBBs to promote cellular proliferation, airway epithelial cells are mostly quiescent owing to the polarized segregation of NRG from its receptors. In differentiated airway epithelial cells, NRG is exclusively secreted into the apical fluid, and ERBBs are sequestered basolaterally. This configuration yields ligand-receptor pairs that are poised for autocrine activation following the loss of epithelial integrity. Indeed, wounding the epithelial layer activates ERBBs at the wound edge, triggering proliferation and promoting wound closure and restoration of cell polarity; similarly, when apical-basal polarity or tight junctions are experimentally disrupted, NRG gains access to its receptors 44 . In addition to providing a positional cue that guides the distribution of RTKs and their ligands, cell junctions are important transmitters of physical information that can more directly regulate RTKs. For example, the spatial restriction of RTKs at the plasma membrane by the cadherin family of cell-cell adhesion receptors is thought to underlie, in part, the poorly understood phenomenon of contact-dependent inhibition of proliferation [45] [46] [47] . In culture, untransformed cells of many types stop dividing on reaching confluence despite the continued presence of abundant growth factors -even when growth factors are provided to both the apical and basolateral surfaces. The localization of receptor tyrosine kinases (RTKs) to either the apical or basolateral surface dictates whether they can be activated by secreted ligands. For example, activation of RTKs can be promoted by directing their localization to either the apical or the basolateral surface where they can interact with luminally or basolaterally provided ligands. Alternatively, activation of RTKs can be prevented by sequestering them from their ligand by cell polarization. Loss of polarity is a hallmark of epithelial cancers that most certainly yields altered spatial distribution of RTKs. Without defined apical and basolateral surfaces to which RTKs can be targeted and segregated from one another and/or their ligands, RTKs in depolarized cells can dimerize with receptors and/or be activated by ligands that are not normally available in a polarized cell, resulting in aberrant RTK signalling. AJR, apical junctional region.
Crypt-villus axis
The longitudinal or vertical axis formed by a villus and its corresponding crypts in the small intestine.
Therefore, signalling from RTKs can be inhibited by cell-cell contact. In vivo, all cells in a given tissue are in contact; therefore, this process must be overridden during development and tissue homeostasis.
In non-confluent endothelial cells, vascular endothelial growth factor (VEGF) induces activation and internalization of VEGF receptor 2 (VEGFR2), yielding continuous mitogenic signalling 45, 46, 48 . By contrast, confluent cells do not proliferate in response to VEGF; instead, VEGFR2 associates with vascular endothelial cadherin (VE-cadherin) at adherens junctions and is not internalized. It has been proposed that the densityenhanced phosphatase 1 (DEP1), which is also recruited to adherens junctions, mediates the dephosphorylation of VEGFR2, preventing internalization and continuous proliferative signalling 45, 46 . Consistent with these findings, blocking VE-cadherin function or expression in three-dimensional endothelial cultures enhances VEGFR2-dependent sprouting 49 . In response to cell-cell contact, EGFR can also be restricted to a non-signalling, non-internalizing plasma membrane compartment 47, [50] [51] [52] [53] . This property is dependent on E-cadherin engagement and, importantly, seems to reflect the ability of the cells to sense the amount of cadherin-mediated contact with which they are engaged. For example, cadherin levels, cell junction 'status' (that is, mature or remodelling), strength of adhesion to the underlying extracellular matrix (which, in turn, controls the extent of cell-cell contact) and position within a cluster of cells can all profoundly affect EGFR activity within individual cells, in turn, creating spatial patterns of EGFR activity in multicellular tissues 47, 52, 53 . The mechanistic basis of this remains to be elucidated, but could reflect altered RTK clustering and signalling as a consequence of cell shape-driven changes in cortical cytoskeletal organization. Regardless of the mechanism, these data suggest that physical parameters within a tissue can directly contribute to the spatial control of RTK signalling.
Dynamic localization of RTKs in tissues.
Beyond the constitutive spatial distribution of RTKs within mature polarized epithelia, the transient spatial restriction of RTKs contributes to dynamic processes such as directed cell migration, tissue morphogenesis and angiogenesis 54, 55 . Border cells in the Drosophila melanogaster ovary provide a compelling example of the role of spatial RTK localization during directed cell migration in vivo (reviewed in REF. 56 ). The anterior follicular epithelium within the fly ovary contains a group of border cells that invade the underlying germline tissue and migrate to the posterior-localized oocyte. Studies from several groups have revealed that two RTKs expressed on border cells, EGFR and platelet-derived growth factor (PDGF)/ VEGF-related receptor (PVR), sense ligands expressed by the oocyte, and direct the border cells to them 56 . During this process, spatially localized RTK activity is required for proper guidance (FIG. 4a) . Jekely et al. found that inhibiting endocytosis in border cells yields the loss of leading edge phosphotyrosine (facing the source of ligand), delocalized guidance signalling and severe migration defects, suggesting that endocytosis of active RTKs at the leading edge facilitates their recycling and continued reception of the directional cue 56, 57 . Spatial patterning of RTK activity can also have a central role in the dynamic processes of tissue morphogenesis and homeostasis. An example is given by the differential localization of EPHs and ephrins that controls cell positioning along the crypt-villus axis during intestinal epithelial homeostasis (FIG. 4b) . Bidirectional signalling establishes a physical boundary between adjacent EPHB-and ephrin B1-expressing cells 58 . This occurs via a mechanism in which EPHB signalling activates the metalloproteinase ADAM10 at sites of cell-cell adhesion, inducing the shedding of E-cadherin at EPHB-ephrin B1 contacts and decreasing the affinity between the two cell populations 59 . It is thought that migration out of the crypt may be regulated by such differential adhesion 59 . In addition, the position of the EPHB-ephrin B1 boundary along the crypt-villus axis affects the exposure of cells to other signals such as WNT; in this way EPHB-ephrin B1 patterning controls both proliferation and differentiation during intestinal homeostasis 60 . This example illustrates a reiteratively used principle during morphogenesis and homeostasis: the cell that provides the RTK signal defines itself as distinct from the cell that receives it. In another well-studied example (FIG. 4c) . During angiogenic sprouting, the tip cell itself localizes VEGFR2 and VEGFR3 specifically to filopodia, where they detect an extracellular gradient of VEGF ligand to direct filopodial extension and sprouting 65, 66 .
Control of intracellular RTK localization.
Although conventional models depict RTKs that signal from the plasma membrane before undergoing endocytosis to attenuate signalling, mounting evidence indicates that RTKs remain active in endosomal compartments (reviewed in . In fact, for some RTKs, internalization is required for a complete signalling response. Moreover, certain RTKs can activate distinct effectors from the plasma membrane versus the endosome, yielding another level of spatial control (axial). The idea that endosomes sustain and localize RTK signalling within the cell instead of merely attenuating it was originally put forward in the mid-1990s by Bergeron and colleagues, who observed that, shortly after EGF stimulation, most activated EGFR co-localized with its associated signalling molecules SHC, GRB2 and SOS in early endosomes, suggesting that signalling continues from this compartment 70, 71 . To confirm this idea, Vieira et al. blocked endocytosis using a dominantnegative dynamin mutant and showed that inhibiting EGFR internalization resulted in phosphorylation of phospholipase C-γ1 and SHC, but significantly reduced activation of ERK1-2 and PI3K, indicating that different sets of signalling molecules are activated on the plasma membrane versus endosomes 72 . In another example, inhibition of nerve growth factor (NGF)-induced internalization of the RTK TRKA (also known as NTRK1) in PC12 cells enhanced survival responses mediated by TRKA-dependent activation of PI3K and AKT at the plasma membrane, but inhibited differentiation mediated by TRKA-dependent ERK1-2 activation in endosomes 73 . In fact, NGF stimulates the assembly of a stable signalling complex containing TRKA, RAP1 and ERK1-2 in endosomes that is not formed at the plasma membrane; thus, differentially localized RTKs can transmit distinct signals, making axial spatial regulation a crucial factor in determining their biological output 74 (FIG. 4d) .
More recent studies have demonstrated that other RTKs also continue to signal from endosomes, including the insulin receptor 75 , PDGF receptor (PDGFR) 76 , VEGFR2 (REFS 46, 77) and VEGFR3 (REF. 78 ). As receptor-effector pairing at the plasma membrane and on endosomes varies among receptors, controlling the Bidirectional signalling establishes a physical boundary between adjacent EPHB-and ephrin B1-expressing cells via an E-cadherin-mediated mechanism that alters cell-cell adhesion between these cell types. c | VEGF receptor (VEGFR) helps to define the identity of tip cells during angiogenic sprouting. Expression of VEGFR in the tip cell induces Delta-like 4 (DLL4), increasing Notch signalling and downregulating VEGFR2 expression in neighbouring stalk cells. Tip cells localize VEGFR2 and VEGFR3 to filopodia to direct their migration towards a VEGF gradient. d | Activated RTKs can have distinct signalling outputs depending on their plasma membrane or endosomal localization. In fact, some RTKs -including EGFR and TRK -can assemble different signalling complexes depending on their axial localization (signalling responses A and B). Several RTKs can also elicit distinct signalling responses from the nucleus (signalling response C 
Axon terminal
The distal termination of a presynaptic neuron.
Cell body
The part of a neuron containing the nucleus and surrounding cytoplasm, but not the axonal and dendritic extensions. internalization machinery could equate to different signalling outcomes for distinct RTKs. Endosomal signalling may also confer several advantages to the cell, such as increased signalling specificity and protection from cytosolic phosphatases, ubiquitin ligases and proteases. Moreover, endosomes can act as transport modules, using microtubule motors to provide the rapid delivery of signals from the plasma membrane to targeted subcellular locations that may be quite a distance away. For example, on NGF-mediated activation of TRKA at an axon terminal, endosomal transport of the active NGF-TRKA complex along the axon to the cell body is required to promote signalling events in the nucleus 79, 80 . In fact, this provides a fascinating example of how lateral and axial regulation can be integrated. Neurotrophinmediated (NGF and brain-derived neurotrophic factor (BDNF)) stimulation of TRK receptors on the cell body leads to activation of ERK1-2 and ERK5 in the nucleus; by contrast, stimulation of TRK receptors on distal axon terminals activates ERK1-2 and ERK5 locally, but selectively activates only ERK5 in the nucleus following endosomal transport to the cell body 81 . Importantly, these ERK family MAP kinases activate distinct groups of transcription factors; thus, the lateral localization of TRK receptors on the neuronal plasma membrane, as well as the axial transport of activated TRK signalling complexes, combine to influence gene expression. Beyond endosomal signalling, RTKs themselves have been reported to travel from the cell surface to the nucleus where they may have additional biological outcomes owing to their roles in transcriptional regulation and DNA repair (BOX 2; FIG. 4d) .
Spatial deregulation of RTKs in cancer
Recognition of the importance of spatially regulating RTKs in normal cells and tissues is accompanied by the realization that the role of spatial deregulation of RTKs in tumorigenesis may be vastly underappreciated. In addition to the recent identification of oncogenic mutations that spatially deregulate specific RTKs, spatial deregulation is likely to be a primary consequence of other well-known oncogenic mutations and phenotypic hallmarks of tumour cells. For example, overexpression, amplification or mutation of RTKs themselves can alter their spatial distribution. Alternatively, spatial deregulation of RTK signalling may underlie the prominent occurrence of altered trafficking, polarity, cell adhesion or cytoskeletal organization in cancer development and progression. The development of high-resolution methods for detecting RTK activity in normal and tumour tissues will be essential for studying the role of spatial RTK patterning in the heterogeneous tumour environment. Spatial regulation could dramatically affect both the response of tumours to targeted RTK inhibitors and the subsequent mechanisms of resistance that emerge.
Altered lateral RTK distribution in tumour cells.
Gene amplification or overexpression is a common mechanism of RTK deregulation in many cancers that not only yields increased surface abundance and signalling, but that is also likely to alter the lateral distribution, clustering and dimeric partnering of RTKs (FIGS 1,2b ). For example, many studies suggest that ERBB2 amplification alters the complex equilibrium of ERBB2-and ERBB3-containing dimers and/or clusters in breast cancer cells, consequently shifting their signalling output and dependencies 12, [82] [83] [84] [85] . Similarly, MET amplification can drive ERBB3-dependent PI3K signalling, thereby mediating lung tumour resistance to EGFR inhibitors 86, 87 . Although the mechanism is unknown, this is thought to occur via physical collaboration between MET and ERBB3, which MET does not normally activate 86 . Although ERBB family members and other RTKs are amplified or overexpressed in many cancers, few studies have examined how an increase in one RTK affects the spatial equilibrium and signalling output of others.
Alterations in proteins that compartmentalize the plasma membrane and confer spatial control of RTKs are also found in many cancers (FIG. 2b) . For example, mutation or deregulation of caveolin 1 (CAV1), an architectural component of caveolae (a subset of lipid rafts) occurs in a variety of human cancers. By binding and sequestering certain receptors -including EGFR and ERBB2 -at the plasma membrane, CAV1 can inhibit proliferative signalling and may thus function as a tumour suppressor 88, 89 . Indeed, the CAV1 gene is located in a chromosomal region that is frequently deleted in several tumour types 90, 91 . Similarly, a dominant-negative CAV1 mutation is found in a subset of primary human breast cancers 92 . By contrast, CAV1 is re-expressed or maintained in some advanced metastatic tumours, often correlating with a poor prognosis 91, 93 . In fact, it has recently been reported that hypoxia-induced upregulation of CAV1 promotes clustering of EGFR
Box 2 | Emerging roles of nuclear RTKs
Numerous reports describe the translocation of receptor tyrosine kinases (RTKs), including epidermal growth factor receptor (EGFR), ERBB2, ERBB3, ERBB4, fibroblast growth factor receptor (FGFR), TRKA and MET, to the nucleus (reviewed in . Nuclear EGFR, first reported in hepatocytes during liver regeneration, has been the most extensively studied 144 . The carboxyl terminus of EGFR displays intrinsic transactivation activity and can activate target genes such as CCND1 (encoding cyclin D1), AURKA (encoding Aurora kinase A), NOS2 (encoding nitric oxide synthase 2, inducible) and MYBL2 (encoding myb-like protein 2), promoting cell proliferation and genome instability (reviewed in REFS 142, 143) . Nuclear EGFR has also been reported to promote DNA repair, replication and radio-resistance by activating DNA-dependent protein kinase (DNA-PK), and/or phosphorylating and stabilizing chromatin-bound proliferative cell nuclear antigen (PCNA). The presence of nuclear EGFR has been reported in several cancers, and is associated with a poor prognosis; for example, nuclear localization of a constitutively activated EGFR variant, EGFRvIII, has been correlated with poor clinical outcome in prostate cancer, invasive breast cancer and glioblastoma [145] [146] [147] . Moreover, several reports suggest that nuclear EGFR is associated with resistance to conventional chemotherapies and to EGFR-targeted therapies (reviewed in REFS 142, 143) . Nuclear ERBB2 and ERBB3 have also been reported in cancer; in fact, like EGFR, increased levels of nuclear ERBB3 correlate with advanced prostate cancer 148, 149 . Given their correlation with poor clinical outcome and their role in therapeutic resistance, nuclear ERBB receptors are emerging as important biomarkers in cancer and therapeutic response. It is not clear, however, how intact RTKs are transported from their plasma membrane localization into the nucleus. Rather, the best-characterized route of RTK nuclear localization relies on proteolytic cleavage by membrane-associated proteases to release cytoplasmic RTK fragments that are transported into the nucleus by conventional mechanisms (reviewed in REFS 140, 150) . Clearly, a realization of their potential as biomarkers will require a greater understanding of these mechanisms.
Epithelial-to-mesenchymal transition (EMT).
A programme by which cells convert from an epithelial to a mesenchymal phenotype. This process, which is enacted during normal embryonic development, can be abnormally activated in carcinomas, resulting in altered cell morphology, the expression of mesenchymal proteins and increased invasiveness.
within caveolae, leading to ligand-independent activation 94 . This complex relationship between CAV1 expression and tumorigenesis is likely to depend on whether the RTKs that are active in a specific tumour normally use caveolae to inhibit or enhance signalling. Similarly, alterations in components of the clathrin machinery and subsequent steps in vesicular trafficking are frequently found in human cancer (FIG. 2b) .
Alterations in cortical cytoskeleton organization and function are also likely to alter RTK distribution, clustering and signalling in a cell-autonomous manner. In support of this, an intriguing recent study found that the actomyosin-dependent mobility of activated EPHA2 receptors in the plasma membrane of breast cancer cells is highly correlated with their metastatic potential 26 . In another example, the cortical cytoskeleton-associated neurofibromatosis type 2 (NF2) tumour suppressor, merlin, can control the lateral mobility and distribution of activated EGFR in the plasma membrane 47, 95 . Altered RTK distribution in tumour tissues. Loss of polarity and contact-dependent inhibition of proliferation are early and universal hallmarks of tumorigenesis 96, 97 . Given the role of apical-basal polarity and cell-cell junctions in spatially controlling RTK signalling, alterations of essential cell polarity or cell junction components will almost certainly yield deregulated RTK activity (FIG. 3) . In fact, several key cell polarity and cell junction proteins have tumour suppressor activity in vivo.
Apical-basal polarity is maintained by the Crumbs, PAR and Scribble polarity complexes. The first indication that deregulated polarity could contribute to tumorigenesis was provided by studies in D. melanogaster that revealed that loss-of-function mutations in Scribble complex proteins resulted in both mislocalization of apical determinants to the basolateral membrane and in uncontrolled proliferation 98 . Altered expression or mislocalization of Scribble and other polarity proteins have also been reported in many human cancers 97, [99] [100] [101] [102] [103] . Although RTKs have not yet been directly implicated in the neoplastic phenotype exhibited by D. melanogaster polarity mutants, it is notable that genes that encode several endocytic proteins have been identified as either modifiers of polarity mutants or as tumour suppressors themselves 104 . Moreover, a recent study in zebrafish revealed that loss of a Scribble complex protein, Lethal giant larvae (Lgl), results in the activation of ERBB signalling, which in turn drives epidermal proliferation and induction of the epithelial-to-mesenchymal transition (EMT) 105 . This finding suggests that aberrant RTK activation may underlie the overproliferation phenotypes of polarity mutants. Mounting evidence indicates that autocrine activation of RTKs occurs in many human cancers, including ERBB3 in lung, ovarian, and head and neck cancers [106] [107] [108] . Although aberrant ligand production may be responsible in some tumours, the cell-autonomous ligand-receptor interactions that are permitted following loss of polarity may be an underappreciated mechanism of autocrine RTK signalling in human cancer.
Alterations in the cell adhesion machinery have also been implicated in human cancer, and, in this case, deregulated RTK signalling has been directly implicated. For example, loss of E-cadherin has been linked to the initiation and/or progression of many cancers. Germlineinactivating mutations in CDH1 (which encodes E-cadherin) can cause diffuse gastric cancer in humans; deregulated EGFR signalling has been linked to the inherent invasive behaviour of these tumours 109, 110 . In fact, loss of E-cadherin is also a hallmark of EMT that is thought to drive malignant progression 111 . Aberrant EGFR signalling also accompanies EMT in many cancers, in which EMT is associated with resistance to EGFR inhibitors 112 . Indeed, the obvious parallels between the invasive behaviour of tumour cells and coordinated cell movements during development -including both EMT and the example of RTK-driven border cell migration in D. melanogasterstrongly suggest that aberrant spatial activation of RTKs contributes to tumour invasion driven by a loss of polarity, contact-dependent inhibition of proliferation and EMT. In support of this, recent studies suggest that, as in border cell migration, the endocytic turnover of PDGFR drives the invasive properties of glioblastoma cells and the recycling of EGFR (coupled with α5β1 integrin) drives the migration of ovarian cancer cells 113, 114 . Loss or mutation of α-catenin (which is encoded by CTNNA1), an essential core component of the adherens junction, has also been found with increasing prevalence in human cancers 115 . In fact, the NF2 tumour suppressor, merlin, which stabilizes adherens junctions and directly interacts with α-catenin, mediates contact-dependent inhibition of EGFR internalization and signalling 47, 116 . Pharmacological inhibitors of EGFR can reverse the overproliferation of merlin-deficient cells in culture and in vivo, underscoring the role of deregulated RTK signalling in merlin-deficient tumours 47, 117, 118 . It is now appreciated that a tumour is not a uniform collection of cells but rather a heterogeneous and interdependent community of cells that interact with each other and with surrounding normal cells 96, 119 . Thus, the patterned distribution of RTK activity among cells in the tumour environment could have a crucial role in the initiation and progression of many tumour types (FIG. 5) . The EPHs once again provide a glimpse into how important spatial RTK distribution might be in this context. Recent studies in mice have shown that loss of EPHB-mediated cell compartmentalization in the intestine completely alters adenoma formation that is induced by mutation of the adenomatous polyposis coli (Apc) tumour suppressor, ultimately rendering them larger, more numerous and more advanced 120 (FIG. 5a) . Prostate cancer cells can also use EPH signalling to promote aberrant interactions with stromal cells, thereby facilitating invasive behaviour 121 (FIG. 5b) . Thus, patterns of RTK activation in the developing tumour and microenvironment might have a central role in the biology of the tumour. spatial restriction of RTK signalling both indirectly and directly. As plasma membrane macrodomains require vesicular trafficking to maintain their identities, RTK localization can be altered indirectly by the disruption of these domains. For example, cell-cell junctions and apical-basal polarity are dynamically maintained by the constitutive endocytosis and recycling of membrane components 123 . Disrupted trafficking can yield loss of cell-cell junctions and polarity, abolishing the differential localization of RTKs to apical and basolateral membrane domains (FIG. 3) . Impairing or enhancing endocytosis and/or recycling can also directly alter receptor distribution (FIG. 2b) . Many of the alterations in endocytic or recycling components that have been identified in human tumours would be predicted to enhance the recycling of RTKs and to decrease their trafficking to lysosomes.
Altered axial RTK distribution in tumours.
Recent studies directly support a role for altered trafficking in oncogenic RTK signalling. In the following examples, oncogenic mutations in RTKs that are found in human malignancies alter their own trafficking 124, 125 . The RTK fms-related tyrosine kinase 3 (FLT3) is expressed on haematopoietic progenitor cells and regulates their survival, proliferation and differentiation. Internal tandem duplication (ITD) mutations in the juxtamembrane domain of FLT3 (FLT3-ITD) not only yield constitutive ligand-independent activation of the receptor, but also impair its delivery to the plasma membrane, resulting in intracellular signalling. Activation of FLT3-ITD in intracellular compartments yields activation of signalling pathways that are distinct from those that are activated by the plasma membrane-localized receptor. Although plasma membrane-targeted FLT3-ITD strongly activates the AKT and ERK1-2 pathways, intracellular FLT3-ITD aberrantly activates signal transducer and activator of transcription 5 (STAT5), an event that is recognized as an important step in myeloid transformation 124 . Another recent study demonstrated that both activation and increased endosomal signalling are necessary for the tumorigenic and metastatic properties of MET (REF. 125 ). Two distinct MET kinase domain mutations (MET D1246N and MET
M1268T
) identified in human papillary renal carcinomas render the receptor constitutively active and promote in vitro cell migration and growth in soft agar. Blocking endocytosis by numerous methods, including mutation of the GRB2-binding site on MET, preserved phosphorylation (and thus activation) of MET mutants but prevented their oncogenic behaviour. Topical treatment of MET D1246N -or MET M1268T -expressing tumours with endocytic inhibitors also prevented subcutaneous tumour growth. Surface biotinylation assays demonstrated constitutive internalization and recycling, as well as impaired degradation of MET mutants compared with wild-type MET; however, the mechanisms by which cells sort the mutants to recycling endosomes while targeting wild-type MET for degradation are not yet known. The identification of these pathways will be essential in order to therapeutically exploit their differences.
Therapeutic implications
Deregulated RTK signalling has been causally implicated in the development and progression of nearly all types of cancer, prompting a major effort to develop and test pharmacological inhibitors of various RTKs 126 . Most translational studies measure overall RTK pathway strength using fairly uniform populations of cultured cells derived from individual tumours -usually permanent cell lines established under the selective pressures imposed by tissue culture conditions. However, the spatial distribution of RTK activity within individual cells and within the evolving tumour could substantially affect the success of such targeted therapies.
For example, differences in RTK dimerization and clustering caused by gene amplification, increased expression, distinct mutations or altered physical parameters such as loss of polarity or ECM stiffness could promote ligand-independent or kinase-independent activation of homotypic or collaborating RTKs. This could have a dramatic impact on the efficacy of ligand-blocking antibodies, such as the EGFR inhibitor cetuximab, or on antibodies that disrupt the interaction of a specific RTK-containing dimer, such as the ERBB2 dimerization inhibitor pertuzumab 127, 128 . Even fairly subtle differences in clustering equilibrium among RTKs within individual tumour cells could substantially influence the pharmacodynamics of a particular drug.
Altered axial distribution of RTKs could also have a dramatic impact on therapeutic efficacy. For example, an RTK mutation that drives aberrant signalling from within the endosome may not be targetable by ligand-blocking or other inactivating antibodies. Similarly, in some cases, tumour cells express high levels of cleaved, intracellular or even nuclear forms of a particular RTK; these may also be differentially sensitive to available targeted therapies 129 . Spatial differences in RTK activity across the heterogeneous tumour microenvironment could also affect tumour responsiveness to targeted therapies; for example, spatial deregulation of a particular RTK could drive invasion at the leading edge of the tumour but not proliferation in the tumour centre, or vice versa.
Finally, the spatial distribution of RTKs in the tumour and microenvironment could also be key drivers of resistance mechanisms. For example, the expansion of MET-amplified, ERBB inhibitor-resistant lung tumour cells may be promoted by local, stroma-produced hepatocyte growth factor (HGF) ligand 87 . Tumour cells that commandeer an environmentally produced ligand (for example, HGF) would respond differently from those that acquire ligand-independent mechanisms of activation (FIG. 5c) . Therefore, the position of a cell in a tumour mass may considerably affect its behaviour during the evolution and therapeutic response of the tumour.
The concept of personalized medicine -developing a treatment plan that is based on the molecular signature of a tumour -has become a major focus of cancer research. Current efforts aim to define the gene mutation, mRNA expression, and epigenetic and proteomic signatures of individual tumours. The spatial distribution of therapeutic targets (such as RTKs) within individual cells and across a tumour could also have a dramatic impact on therapeutic efficacy; however, we still do not know precisely how or where many clinically used RTK inhibitors function. In fact, structural models of RTK dimerization, activation and pharmacological inhibition are far from complete. Recent efforts to design fluorescently labelled versions of these drugs will provide excellent tools for probing their sites of action, and evolving structural models will lead to a greater understanding of exactly how these inhibitors function. Ultimately, this information could be exploited to design novel drugs that specifically regulate the distribution of RTKs or that specifically target a spatially localized population of RTKs.
Perspectives
The work of biochemists and cell biologists has yielded large bodies of work devoted to plasma membrane architecture and vesicular trafficking as a means of spatially controlling receptors of all kinds. Likewise, developmental biologists, often studying model organisms, have uncovered some of the ways that cells spatially choreograph receptor signalling to drive tissue morphogenesis. The appreciation of the near-universal role that RTKs have in human cancer has cast a spotlight on this important class of mitogenic receptors and has effected an explosion of interest in RTKs as therapeutic targets. To maximize the promise of this translational focus it will be crucial to bring developmental biologists, membrane receptor biologists and translational investigators together to assemble a three-dimensional view of RTK activity in normal and tumour cells, and tissues.
